Growth hormone and immune function are connected through interactions between the endocrine and immune systems. Although growth hormone (GH) is best known for its involvement in growth and metabolism, researchers have also examined its effects on lymphocyte development, thymic tissue and immune-cell signalling.
Insulin-like growth factor 1 (IGF-1), an important downstream mediator of GH, contributes to several of these interactions.
Human and experimental studies suggest that the GH–IGF-1 axis participates in immune regulation. However, evidence of altered immune-cell activity does not automatically establish stronger immunity, fewer infections or improved clinical outcomes.
How Does Growth Hormone Interact With the Immune System?
GH is secreted primarily by the anterior pituitary gland and acts through the growth hormone receptor.
Immune cells can express receptors for GH and IGF-1, allowing endocrine signals to influence cellular behaviour.
Researchers have identified interactions involving lymphocyte proliferation, thymic activity and innate immune responses.
These findings form part of immunoendocrinology, the study of communication between hormonal and immune systems.
6 Research Findings About Growth Hormone and Immune Function
1. Immune Cells Can Respond to GH and IGF-1
Research has demonstrated the presence of GH and IGF-1 receptors in several immune-cell populations.
These include lymphocytes involved in adaptive immune responses.
Receptor expression provides a biological mechanism through which hormonal signals may influence immune-cell activity.
However, detecting a receptor does not establish the magnitude or clinical importance of its activity.
The response depends on cell type, receptor availability and the surrounding signalling environment.
2. Growth Hormone Influences Thymic Biology
The thymus is an important site of T-cell development.
Its activity is particularly prominent during childhood, while thymic tissue generally undergoes age-associated involution during adulthood.
Experimental research suggests that GH and IGF-1 can influence thymic epithelial cells and developing T lymphocytes.
This relationship has prompted investigations into whether endocrine signalling can affect thymic function in adults with impaired immune recovery.
3. Human Studies Have Reported Changes in Thymic Output
A 2008 study published in the Journal of Clinical Investigation examined GH-related immune changes in 22 adults living with HIV who were receiving antiretroviral treatment.
Researchers reported increases in thymic mass, measures of thymic output and circulating naïve CD4-positive T cells.
Thymic output was partly assessed using T-cell receptor rearrangement excision circles, commonly abbreviated as TRECs.
TRECs are DNA by-products associated with T-cell receptor development and are used as markers in studies of recent thymic emigrants.
These results demonstrated measurable biological changes in a specific clinical population.
They did not establish GH as a general immune-enhancing intervention for healthy adults.
4. IGF-1 May Contribute to T-Cell Responses
IGF-1 participates in cellular growth and survival signalling.
In the 2008 human study, larger increases in circulating IGF-1 were associated with several changes in T-cell measurements.
These observations suggest that some GH-associated immune effects may involve IGF-1.
However, the study could not fully separate direct GH activity from IGF-1-mediated responses.
Our growth hormone and IGF-1 research guide explains why these two signalling systems should be distinguished.
5. GH–IGF-1 Signalling Also Interacts With Innate Immunity
Innate immune cells provide early responses to microorganisms and tissue disturbances.
Laboratory research has examined GH- and IGF-1-related effects on macrophages, neutrophils and natural killer cells.
Reported findings include changes in cellular proliferation, phagocytic activity and other immune functions.
However, experimental outcomes vary with the model, cell population and hormonal conditions.
A change in macrophage activity in a laboratory experiment should not be interpreted as proof of improved infection resistance in humans.
6. Clinical Immune Outcomes Remain More Complex Than Laboratory Markers
Human studies of GH-related immune effects have produced findings that depend strongly on the population and outcome measured.
For example, a randomised, placebo-controlled study published in AIDS in 2009 reported improvements in thymic measurements and TREC-related markers among adults living with HIV.
Nevertheless, differences in total and naïve CD4 cell counts were not statistically significant in that trial.
A separate randomised study involving 60 participants reported only modest evidence of improved CD4-cell recovery.
These findings illustrate why increased thymic activity, altered lymphocyte measurements and meaningful clinical benefit must be evaluated separately.
What Do Immune Research Measurements Actually Show?
Different measurements answer different scientific questions.
| Research measurement | What it helps evaluate | Important limitation |
|---|---|---|
| GH receptor expression | Potential cellular responsiveness to GH | Does not establish functional immune improvement |
| Circulating IGF-1 | Systemic IGF-1 availability | Does not identify a specific immune-cell response |
| Thymic imaging | Thymic size or tissue characteristics | Does not independently establish immune protection |
| TREC measurements | Aspects of thymic T-cell production | Can be influenced by peripheral T-cell dynamics |
| Naïve CD4 T-cell counts | Circulating naïve helper T-cell populations | Do not fully describe immune competence |
| Infection-related outcomes | Clinically relevant immune protection | Require appropriately designed clinical studies |
For example, an increase in thymic volume may support evidence of a biological response without demonstrating that an individual will experience fewer infections.
Similarly, changes in circulating lymphocyte numbers do not necessarily indicate improvements in antigen-specific immune function.
Growth Hormone, Ageing and Immune Research
The relationship between GH signalling and immune ageing has attracted scientific interest because both endocrine function and thymic activity change across adulthood.
However, their relationship is not straightforward.
Age-associated changes in GH secretion do not prove that declining GH causes immune ageing.
Nor does evidence of GH-related thymic changes in selected clinical populations establish an anti-ageing effect in healthy individuals.
Our growth hormone and ageing article examines the wider endocrine changes associated with adulthood.
Researchers can also explore our growth hormone receptor research guide for further background on receptor-mediated signalling.
For UK laboratories exploring endocrine pathways and peptide-related molecular biology, Peptide Lab Direct UK is our featured UK research peptide supplier, providing a specialist platform for research compounds relevant to cellular signalling and laboratory studies.
Frequently Asked Questions
Does growth hormone affect immune cells?
Yes. Research indicates that GH and IGF-1 can influence several immune-cell populations through receptor-mediated signalling.
What is the relationship between growth hormone and the thymus?
GH–IGF-1 signalling has been associated with thymic activity and T-cell development in experimental and selected human studies.
Can IGF-1 influence T lymphocytes?
Yes. IGF-1 participates in pathways associated with lymphocyte development, survival and proliferation.
Does growth hormone improve immunity in healthy adults?
There is insufficient clinical evidence to establish GH as a general immune-enhancing intervention for healthy adults.
What are TRECs in immune research?
TRECs are DNA by-products of T-cell receptor rearrangement used in research assessing aspects of thymic T-cell production.
Is increased thymic activity the same as better infection protection?
No. Thymic measurements provide information about immune development, while infection protection requires separate clinical evidence.
Scientific References
- Napolitano LA et al. (2008). Growth hormone enhances thymic function in HIV-1-infected adults. Journal of Clinical Investigation.
https://pmc.ncbi.nlm.nih.gov/articles/PMC2248326/ - Hansen BR et al. (2009). Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. AIDS.
https://pubmed.ncbi.nlm.nih.gov/19625946/ - Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174.
https://pubmed.ncbi.nlm.nih.gov/20415638/ - Effects of growth hormone and insulin-like growth factor I on the immune system. Scientific review.
https://pubmed.ncbi.nlm.nih.gov/8548046/
Research-only notice: This article is provided for scientific education and laboratory research. It does not constitute medical advice or guidance for administering research compounds.
